West Pharmaceutical Services

Q3 2026
Speakers

Oct 29, 2026 · 50 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good day and thank you for standing by. Welcome to the Q3 2026 West Pharmaceutical Services Earnings Conference Call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star one one on your telephone and wait for your name to be announced.

To withdraw your question, please press star one one again. I would now like to hand the conference over to your speaker today, Michelle Polinski, Vice President of Communications.

Passages & reports (2)
  • Good day and thank you for standing by. Welcome to the Q3 2026 West Pharmaceutical Service…
  • question, please press star one one on your telephone and wait for your name to be announc…

Speaker 1

Unverified voice label

Good morning and welcome to West's third quarter earnings conference call, which has been Webcast Live. With me today on the call are West's President and CEO, Michelle Lagarde, and West's Senior Vice President and CFO Bob McMahon. Earlier today, we issued our third quarter financial results. A copy of the press release, along with today's slide presentation containing supplemental information for your reference, has been posted in the investor section of the company's website at investor.westpharma.com.

Later today, a replay of the webcast will also be available in the investor section of our website. Before we begin, we'd like
to remind you that statements made by management during this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. Federal Securities Law. Please refer to the accompanying Safe Harbor Statement in today's presentation and press release, in addition to other disclosures made by the company, such as our 10K and 10Q, regarding the risks to which the company is subject.

During the call, management will also report on certain non GAAP financial measures, including organic net sales, adjusted operating profit, adjusted operating profit margin, free cash flow, and adjusted diluted earnings per
share. The accompanying disclosure statement, as well well as reconciliations of these non GAAP financial measures to the most comparable financial results prepared in conformity with U.S. GAAP, are provided in this morning's press release and today's presentation materials.

I'll now turn the call over to our CEO, Michelle
Lagarde. Michelle? Thank you,

Passages & reports (6)
  • Good morning and welcome to West's third quarter earnings conference call, which has been …
  • release, along with today's slide presentation containing supplemental information for you…
  • to remind you that statements made by management during this call and in the accompanying …
  • 10K and 10Q, regarding the risks to which the company is subject. During the call, managem…
  • share. The accompanying disclosure statement, as well well as reconciliations of these non…
  • Lagarde. Michelle? Thank you,

Speaker 2

Unverified voice label

Michelle, and good morning, everyone. Thanks for joining us today. I'm very pleased to welcome you to our earnings poll. And before getting into the details of our strong third quarter performance, I want to begin by saying what a privilege it is for me to now be part of Team West. Having joined West two months ago, my priority has been spending time with our global teams, visiting our sites around the world, and meeting with our customers and investors.

It's been incredibly rewarding to connect and learn from the company's stakeholder network and start to identify how we can build on our strengths and continue to evolve.

Passages & reports (2)
  • Michelle, and good morning, everyone. Thanks for joining us today. I'm very pleased to wel…
  • two months ago, my priority has been spending time with our global teams, visiting our sit…

These have been valuable conversations, and I'd like to give a few examples. First was my visit to our Eschweiler manufacturing site in Germany. What was immediately apparent was a strong mission-driven culture and teamwork among the colleagues. Confronted with the need to increase output, the team focused on execution and unlocking new efficiencies, for instance by integrating more automation onto the production floor. This effort is helping to expand capacity and support our global network optimization to improve the service levels for our customers.

A great example of our opportunity to
drive more impact from continuous improvement across our company. Second, my conversations with our customers. I've called on the same customers for the last decade, so it wasn't hard to get transparent feedback from ?them. And from all my conversations, a very clear pattern has emerged. REST is firmly on the very short list of preferred partners. Our reputation, combined with our deep technical and regulatory expertise, forms an incredible foundation to build upon. ?

And
we're invited to establish closer relationships with our customers. By doing so, we will understand their current and future needs even better so we can drive innovation adoption faster and, of course, keep earning their business every day by a high quality and delivery performance. A clear path to continue to strengthen our enviable leadership position. These two examples point to the opportunity at C4 West to drive more impact from strengthening our continuous improvement efforts and continuing to develop more strategic customer relations which will provide us with superior insights and allow us to better anticipate their future needs. ?

I'm
therefore super excited to start contributing to our company's strategy and performance, build further on a hundred plus years of accumulated experience, and unlock even more impact from our talented team. And with that, enable our customers to improve the lives of many more patients in need. ?Now let me recap our quarterly performance. I'm pleased to report that we've had a greater quarter, exceeding our expectations for both revenues and earnings.

Revenues of 874 million grew 12% organically,
?and adjusted EPS of $2.66 was up 36% compared to last year. Given this strong performance, we are again raising our top and bottom line full year expectations, which Bob will talk about in more detail. Let me now shift to how our segments performed in the quarter. Our proprietary product segment delivered 16.6% organic growth. ?The highlight was HVP components, which grew 20%, driven by both GLP1 and non-GLP1 components demand, and HVP upgrades.

HUP devices grew 26% organically after adjusting for SmartDose 3.5,
?led by Crystal Zenith and Admin Systems. ?While the West Vantage segment revenues declined 7% organically, the performance was slightly better than expected. As a reminder, the strategy of West Vantage is shifting the business to higher value added parts of drug handling. ?And as a result, we're rolling off legacy programs as the new programs continue to wrap. ?

This
is a muted effect on segment growth this year and next. ?To conclude my remarks, I want to thank our team members for their efforts and amazing work. Our end markets remain strong, our position as the leader is firm, and we will continue to step up our performance to exceed our customers' expectations, which in turn will deliver value to all the stakeholders of West.

Passages & reports (29)
  • These have been valuable conversations, and I'd like to give a few examples. First was my …
  • execution and unlocking new efficiencies, for instance by integrating more automation onto…
  • drive more impact from continuous improvement across our company. Second, my conversations…
  • them. And
  • from all my conversations, a very clear pattern has emerged. REST is firmly on the very sh…
  • And
  • we're invited to establish closer relationships with our customers. By doing so, we will u…
  • clear path to continue to strengthen our enviable leadership position. These two examples …
  • allow us to better anticipate their future needs.
  • I'm
  • therefore super excited to start contributing to our company's strategy and performance, b…
  • Now
  • let me recap our quarterly performance. I'm pleased to report that we've had a greater qua…
  • and
  • adjusted EPS of $2.66 was up 36% compared to last year. Given this strong performance, we …
  • quarter. Our proprietary product segment delivered 16.6% organic growth.
  • The
  • highlight was HVP components, which grew 20%, driven by both GLP1 and non-GLP1 components …
  • led
  • by Crystal Zenith and Admin Systems.
  • While
  • the West Vantage segment revenues declined 7% organically, the performance was slightly be…
  • And
  • as a result, we're rolling off legacy programs as the new programs continue to wrap.
  • This
  • is a muted effect on segment growth this year and next.
  • To
  • conclude my remarks, I want to thank our team members for their efforts and amazing work. …
  • West.

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 2

now turn the call over to Bob to provide more details on our quarter performance and updated guidance. Bob? Thanks, Michelle,

Passages & reports (1)
  • now turn the call over to Bob to provide more details on our quarter performance and updat…

Speaker 3

Unverified voice label

and good morning, everyone. Today I'll provide some additional details on Q3 revenue and take you through the income statement and some other key financial metrics. I'll then cover our updated outlook for the rest of the year. As Michelle mentioned, we had a strong third quarter as revenues of $874 million increased 8.7% on a reported basis and grew 11.9% organically, exceeding our expectations overall.

Price contributed just over four percentage points of growth in the quarter. This strong performance was driven by our proprietary segment, which increased 16.6% on an organic
basis. West Vantage declined 6.6% organically, which was better than expected. Within proprietary, our HPP components business was a standout and now represents 53% of the total company's revenues. Revenues of $467 million grew 20% organically, exceeding expectations.

The performance was broad-based and driven by multiple factors, including robust growth in biologics, continued strength in GLP 1s, and positive HPP product mixed shift. Diving a bit deeper into HPP components, we had another strong
quarter of growth outside of GLP1s, growing high teens organically. This underscores our view that overall injectable market continues to provide runway for both increased volumes from existing and new drugs and for HPP upgrades across our existing portfolio.

Annex 1 regulations have been driving
HPP upgrades in Europe, and we're encouraged by increasing signs of upgrade activity in other geographies as regulatory frameworks continue to raise the bar on containment systems. We have added over 200 upgrade projects this year and believe upgrades can be a multi-year tailwind to our business.

Passages & reports (6)
  • and good morning, everyone. Today I'll provide some additional details on Q3 revenue and t…
  • 8.7% on a reported basis and grew 11.9% organically, exceeding our expectations overall. P…
  • basis. West Vantage declined 6.6% organically, which was better than expected. Within prop…
  • organically, exceeding expectations. The performance was broad-based and driven by multipl…
  • quarter of growth outside of GLP1s, growing high teens organically. This underscores our v…
  • HPP upgrades in Europe, and we're encouraged by increasing signs of upgrade activity in ot…

Our GLP1 HVP business also performed very well, accelerating nicely in the quarter, growing well into the 30s organically. HPP GLP1s represented just under 12% of total revenues in the quarter. We continue to remain optimistic about the long-term growth prospects of the GLP1 category, driven by the continued adoption of existing products, the potential for for expansion into new therapeutic categories, ?the development of next generation molecules, and increasing access in certain markets as generics are launched. ?

Now,
looking at other product categories in the proprietary segment, HVP delivery device revenues were $99 million in the quarter. This was flat on a reported basis and up 26% organically after excluding currency and the impact of the SmartDOS 3.5 domestic ?term. Both Crystal Zenith and admin systems contributed to growth in the quarter. Of note, in Q three we generated twelve million dollars in Smart Dose 3.5 revenue, which wasn't included in our Q3 guidance.

This compared to $30 million in Q3 of last year. Both figures, along with FX,
have been excluded to calculate our organic growth in the quarter. As we've previously mentioned, Smart Dose 3.5 product revenues were $55 million in the second half of last ?year, $30 million in Q3, and another $25 million in Q4. Those figures, along with the $12 million in Q3 of this year, are excluded from our organic growth calculations.

And now that we've closed the transaction and do not expect any additional Smart Dose 3.5 product revenues
going forward, I want to provide the Smart Dose 3.5 revenue details for this year to help you with your modeling for next year. SmartDose 3.5 revenues were $100 million this ?year, $46 million in Q1, $42 million in Q2, ?and $12 million this quarter, as I just mentioned.

Consistent with this year, we will exclude those revenues from next year's organic growth calculations, but this will result in a roughly 290 basis point headwind to reported growth next
?year. And lastly, in standard products, revenues of $163 million were up up 3% on an organic basis. ?Now let's move to our West Bandage segment. West Bandage delivered $146 million in revenue, declining 6.6% on an organic basis, slightly better than expected, as we were able to fully recover the revenue deferred by the cyber incident in Q3 versus Q3 and Q4. ?

As
Michelle stated earlier, the year-on-year decline was expected as incremental sales from new programs were more than offset by the decline associated with the roll off of a CGM program starting this quarter. ?And looking by geography, we delivered solid growth across each of our three geographies. Our smallest geography, Asia Pacific, representing 11% of our total company revenues, grew 42%, led by India and China.

America's grew 12%, while AMEA grew 6%, as good growth in
proprietary was partially offset by the CGM program roll off in West Vantage. ?Now let's take a closer look at the rest of the PL. Total company growth margin was 39.7% in the quarter, up 310 basis points year over year. ?The year on year increase was primarily driven by better than expected proprietary product sales and the associated positive mix shift to HBP components as well as price contribution. ?

We
have been able to offset inflationary pressures on our cost base through good plant performance and some cost recovery via pass-through. ?While West Bandage gross margin was down year-on-year, it improved sequentially. Adjusted operating margins of 25.3% were up 420 basis points compared to the prior year, driven primarily by the gross margin expansion and leveraging our SGNA cost base. We also benefited from improved below-the-line performance in the quarter, as our adjusted tax rate was a better than expected 17%, and we had 70.8 million diluted shares outstanding.

Adding it all up, Q3 adjusted earnings per share were $2.66, up 36% versus last year
and 47 cents above the midpoint of guidance we gave on the last earnings call. Before moving into our updated guidance, I did want to highlight a few additional financial metrics. For the first nine months of this year, we delivered free cash flow, that's operating cash flow left CapEx, of $278 million.

This is roughly a 5% decrease compared to the same period in 2025, due primarily to increases in customers' accounts receivable, as well as increased inventory levels to support our operations, partially offset by lower capital spending. This is an improvement from Q2's results, and we expect
continued improvement in Q4. For the first nine months of 2026, capital expenditures were $125 million, lower than initially planned, and we now expect full-year CapEx to be between $215 ?to $220 million for the year.

This is still within our 6-8% of revenue corridor, albeit at the low
?end. We continue to be focused on investing for growth ?and are kicking off a new wave of meaningful capital investments to expand our HVP finishing capacity both in Europe and the US. That said, we expect to remain in that six to eight percent of revenue range for CapEx spending in the future.

The success of our global operations this year has put us onto
more solid footing as we have been adding and training new shifts and optimizing our global network and increasing capacity. Our Q3 outperformance is a great example of the success of our teamwork. We are well positioned to finish the year strong, and the new HVP finishing capacity expansions will further support growth in the coming years.

Additionally, from a balance sheet perspective, earlier this week,
?we upsized our revolver to $750 million and renewed for another five years, providing balance sheet flexibility. We also continue to return cash to shareholders via our dividends and share repurchase plans. Year to date, ?we paid out $47 million in dividends and just announced our 34th consecutive year of dividend increases with an 18% increase in the dividend in the quarter.

And for this first nine months of this year, we have repurchased just over 2.4 million shares for $685 million. Our
cash flow and strong balance sheet continue to position us well as we deploy capital for growth and deliver value to our shareholders. In summary, we had a strong third quarter that exceeded our expectations on the top and bottom lines, and are pleased that our solid business momentum continues. ?

And
now let me turn to our updated guidance. Given the strong third quarter, we now anticipate full year revenue to be in the range of $3.41 to $3.42 billion. Up from a prior range of $3.345 billion to $3.38 billion. This revised guidance assumes full year 2026 organic sales growth of 11.3% to 11.6%, up from a prior range of 10 to 11%. FX is expected to have a full year benefit of 120 basis points, ?while the SMARTDOS 3.5 divestiture negatively impacts reported growth by 160 basis points.

This translates to Q4 revenues of $820 to $830 million, an improvement from our Q4 implied guidance last quarter, and represents 6 to 7% organic
revenue growth. Consistent with the first nine months of the year, we expect Q4 will be driven by double digit growth in HPB components. This prudent guide absorbs incremental negative FX as the dollar has strengthened in the past month, and the ?West Vantage Q3 pulled forward.

Full year 2026 adjusted EPS is expected to be in the range of $9.38 to $9.48, up from a prior range of $8.85 to $9.05. This now represents growth of 29 to 30%
year over year. We expect full year operating margins to expand almost 300 basis points, driven by gross margin expansion and SGNA leverage. This is above our long-term growth construct of 100 basis points per year improvement, as we have benefited this year from stronger than expected revenue growth, portfolio optimization, mix, and SGA leverage. ?

And
to help you with your models below the line for the full year, we're projecting $5 million of net interest income, a tax rate for the full year slightly lower than 18%, roughly $18 million in affiliate profits, and $1.4 million diluted shares outstanding for the ?year. In summary, we're very pleased with how our business is performing. We're well positioned to finish the year strong, and we look forward to introducing 2027 guidance on our Q4 earnings call in February. ?

Now
I'd like to turn the call back to Michelle for closing comments. Michelle.

Passages & reports (66)
  • Our GLP1 HVP business also performed very well, accelerating nicely in the quarter, growin…
  • driven by the continued adoption of existing products, the potential for for expansion int…
  • the
  • development of next generation molecules, and increasing access in certain markets as gene…
  • Now,
  • looking at other product categories in the proprietary segment, HVP delivery device revenu…
  • term.
  • Both Crystal Zenith and admin systems contributed to growth in the quarter. Of note, in Q …
  • have been excluded to calculate our organic growth in the quarter. As we've previously men…
  • year,
  • $30 million in Q3, and another $25 million in Q4. Those figures, along with the $12 millio…
  • going forward, I want to provide the Smart Dose 3.5 revenue details for this year to help …
  • year,
  • $46 million in Q1, $42 million in Q2,
  • and
  • $12 million this quarter, as I just mentioned. Consistent with this year, we will exclude …
  • year.
  • And lastly, in standard products, revenues of $163 million were up up 3% on an organic bas…
  • Now
  • let's move to our West Bandage segment. West Bandage delivered $146 million in revenue, de…
  • As
  • Michelle stated earlier, the year-on-year decline was expected as incremental sales from n…
  • And
  • looking by geography, we delivered solid growth across each of our three geographies. Our …
  • proprietary was partially offset by the CGM program roll off in West Vantage.
  • Now
  • let's take a closer look at the rest of the PL. Total company growth margin was 39.7% in t…
  • The
  • year on year increase was primarily driven by better than expected proprietary product sal…
  • We
  • have been able to offset inflationary pressures on our cost base through good plant perfor…
  • While
  • West Bandage gross margin was down year-on-year, it improved sequentially. Adjusted operat…
  • from improved below-the-line performance in the quarter, as our adjusted tax rate was a be…
  • and 47 cents above the midpoint of guidance we gave on the last earnings call. Before movi…
  • million. This is roughly a 5% decrease compared to the same period in 2025, due primarily …
  • continued improvement in Q4. For the first nine months of 2026, capital expenditures were …
  • to
  • $220 million for the year. This is still within our 6-8% of revenue corridor, albeit at th…
  • end.
  • We continue to be focused on investing for growth
  • and
  • are kicking off a new wave of meaningful capital investments to expand our HVP finishing c…
  • more solid footing as we have been adding and training new shifts and optimizing our globa…
  • coming years. Additionally, from a balance sheet perspective, earlier this week,
  • we
  • upsized our revolver to $750 million and renewed for another five years, providing balance…
  • we
  • paid out $47 million in dividends and just announced our 34th consecutive year of dividend…
  • cash flow and strong balance sheet continue to position us well as we deploy capital for g…
  • And
  • now let me turn to our updated guidance. Given the strong third quarter, we now anticipate…
  • revised guidance assumes full year 2026 organic sales growth of 11.3% to 11.6%, up from a …
  • while
  • the SMARTDOS 3.5 divestiture negatively impacts reported growth by 160 basis points. This …
  • revenue growth. Consistent with the first nine months of the year, we expect Q4 will be dr…
  • West
  • Vantage Q3 pulled forward. Full year 2026 adjusted EPS is expected to be in the range of $…
  • year over year. We expect full year operating margins to expand almost 300 basis points, d…
  • portfolio optimization, mix, and SGA leverage.
  • And
  • to help you with your models below the line for the full year, we're projecting $5 million…
  • year.
  • In summary, we're very pleased with how our business is performing. We're well positioned …
  • Now
  • I'd like to turn the call back to Michelle for closing comments. Michelle.

Speaker 2

Thank you, Bob. ?The early days for me, I'm incredibly excited about the journey ahead. This year we're on track to deliver over 40 billion highly critical components to our customers. This gives you a good sense of the dimensions of the patient impact our colleagues are focused on delivering. And this is why West is such an incredible company with a great financial profile that allows us to compound EPS consistently and at a high rate.

Looking forward to speaking to more of you
?in the coming weeks and months. And with that operator, we're now ready to take the questions. Thank

Passages & reports (6)
  • Thank you, Bob.
  • The
  • early days for me, I'm incredibly excited about the journey ahead. This year we're on trac…
  • company with a great financial profile that allows us to compound EPS consistently and at …
  • in
  • the coming weeks and months. And with that operator, we're now ready to take the questions…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please limit yourself to one question. If you have a follow-up, you may re-queue. One moment for questions.

Passages & reports (1)
  • Thank you. As a reminder, to ask a question, please press star one one on your telephone a…

Questions & answers

Speaker 0

Our first question comes from Paul Knight with Key Bank Capital Markets. You may proceed.

Passages & reports (1)
  • Our first question comes from Paul Knight with Key Bank Capital Markets. You may proceed.

Speaker unclear

?Thanks

Passages & reports (1)
  • Thanks

Speaker 4

Unverified voice label

very much, Michelle, and congratulations to everybody. The um China excuse me, Asia growth was spectacular at uh 42%. Could you talk to the dynamics there, please?

Passages & reports (1)
  • very much, Michelle, and congratulations to everybody. The um China excuse me, Asia growth…

Speaker 2

Yeah, um, maybe I can start just generally, obviously, small base. Um, and so we're excited about the growth as that market continues to provide uh us with uh lots of new customer opportunities and so I would say um a co a great contributor uh to growth uh this quarter.

Passages & reports (1)
  • Yeah, um, maybe I can start just generally, obviously, small base. Um, and so we're excite…

Speaker 3

Yeah and and and Paul um good morning. Uh this is Bob. Just uh to follow on what uh Michelle is saying, you know, we've been very pleased with the the growth we've had in in Asia Pacific. Uh we've had three consecutive quarters here of very strong growth. You know, it it is a the smaller part of our our our business from a geography standpoint, but it really has been driven uh in India and China, you know, really across a number of different markets.

One is obviously the the um uh uh um uh introduction of uh GLP1s in in both those markets. And as we think
about this over time, I think there is a bigger opportunity to continue to uh drive growth in Asia uh as you think about the innovative drugs that are being developed there and and so forth. And so we've we've certainly had uh it's early days for us, but I think there's an opportunity for us to continue to grow there and excited about the progress today.

Passages & reports (4)
  • Yeah and and and Paul um good morning. Uh this is Bob. Just uh to follow on what uh Michel…
  • the smaller part of our our our business from a geography standpoint, but it really has be…
  • about this over time, I think there is a bigger opportunity to continue to uh drive growth…
  • us to continue to grow there and excited about the progress today.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Daniel Markowitz with Evercore ISI. You may proceed.

Passages & reports (1)
  • next question comes from Daniel Markowitz with Evercore ISI. You may proceed.

Speaker unclear

?Hey, congrats on

Passages & reports (1)
  • Hey, congrats on

Speaker 5

Unverified voice label

the quarter, and thanks for taking my question. Um can you help us understand some of the moving pieces for the GLP1 elastomers between ?the Medicare Bridge program, OUS generics, and then offset by some potential mix shift to multidose? It was a it was a massive record quarter, super impressive. ?Um I was curious, was there anything one time in this three Q number?

And and can you just help us understand the growth outlook here as we turn the page into 27, please?

Passages & reports (5)
  • the quarter, and thanks for taking my question. Um can you help us understand some of the …
  • the
  • Medicare Bridge program, OUS generics, and then offset by some potential mix shift to mult…
  • Um
  • I was curious, was there anything one time in this three Q number? And and can you just he…

Speaker 2

Yeah, well before I turn it over to Bob for for some specifics, the way I would think about it, you know, that class of medicines continues to demonstrate that it's transformative in its nature. Um I would say we're still quite early uh in the um full potential of that class, right? You talked about access, you know, different geographies around the world that are different levels of uh of maturity.

And so we think it's a a durable growth driver uh for us in the in the years to come and certainly nothing one off ish uh in in the quarter. Well

Passages & reports (2)
  • Yeah, well before I turn it over to Bob for for some specifics, the way I would think abou…
  • about access, you know, different geographies around the world that are different levels o…

Speaker 3

yeah I was I was just gonna say to build on that. Um we didn't see any kind of one time um things there. We obviously weren't aren't going to provide any you know granular level of details here, but uh as you uh know very well Dan you know, we do think that this is a longer term opportunity growth for all the reasons that we talked about in the prepared remarks as well as what Michelle just talked about.

You know, uh the bridge program certainly is uh you know one area where it's actually increasing access um and uh we're glad to participate that we in in
that with our with our customers. And then certainly outside the US there's opportunities to continue to grow as uh generics um uh the generic opportunity in um in various markets comes to to bear. And then obviously down the road, you've got opportunities around next generation molecules as

Passages & reports (3)
  • yeah I was I was just gonna say to build on that. Um we didn't see any kind of one time um…
  • is a longer term opportunity growth for all the reasons that we talked about in the prepar…
  • that with our with our customers. And then certainly outside the US there's opportunities …

Speaker unclear

?well.

Passages & reports (1)
  • well.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from Matt LaRue with William Blair. You may proceed.

Passages & reports (1)
  • Our next question comes from Matt LaRue with William Blair. You may proceed.

Speaker unclear

?Hi,

Passages & reports (1)
  • Hi,

Speaker 2

good morning, uh everyone. I wanted to actually ask on HVP devices, which you know sort of act smart tooth have continued to be strong this year. ?Um is that associated with any particular drug launch or or new customer wins, or perhaps is this indicative of customers asking you to do more and sort of a broadening opportunity set for for that category? Thanks.

Passages & reports (3)
  • good morning, uh everyone. I wanted to actually ask on HVP devices, which you know sort of…
  • Um
  • is that associated with any particular drug launch or or new customer wins, or perhaps is …

Speaker unclear

?Yeah

Passages & reports (1)
  • Yeah

Speaker 3

let me take that uh Matt uh and good morning. Yeah we've been very pleased with um with that that part of the business. ?I wouldn't say it's in it's indicative of any one particular um new launcher molecule. I I think you know as we talked about you know Crystal Zenith and both uh the admin systems, they got a number of different customers and broad-based across uh you know different markets uh as well. ?

And
so we've just been able to see uh I think nice uh kind of broad-based uh growth there. I would say, you know, as we think about Q4, sometimes that business um can be a little lumpy. Um ?I wouldn't say that there was any pull forward, but it had a very strong Q4 of last year. And so we're not expecting the same kind of growth that we saw in Q3 to repeat in Q4.

But that being said, you know, we're continuing to work with um uh partners also on the self-injection
uh system the next generation smart dose 10 and and so forth and uh um ?so feel good about that portfolio going forward

Passages & reports (10)
  • let me take that uh Matt uh and good morning. Yeah we've been very pleased with um with th…
  • I
  • wouldn't say it's in it's indicative of any one particular um new launcher molecule. I I t…
  • And
  • so we've just been able to see uh I think nice uh kind of broad-based uh growth there. I w…
  • I
  • wouldn't say that there was any pull forward, but it had a very strong Q4 of last year. An…
  • uh system the next generation smart dose 10 and and so forth and uh um
  • so
  • feel good about that portfolio going forward

Speaker 0

thank

Passages & reports (1)
  • thank

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker unclear

?our

Passages & reports (1)
  • our

Speaker 0

next question comes from Justin Bowers with Deutsche Bank you may proceed

Passages & reports (1)
  • next question comes from Justin Bowers with Deutsche Bank you may proceed

Speaker 6

Unverified voice label

Bonjour Michel appreciate you sharing your initial observations in your first first two months at West. Can you discuss your priorities over the next six to twelve months and also some of the opportunities you see to fortify West Smo.

Passages & reports (1)
  • Bonjour Michel appreciate you sharing your initial observations in your first first two mo…

Speaker 2

Yeah, no, thanks for the question. It's been a great first two months. Able to have spent time with our colleagues around the sites and the w around the world. Um spent a lot of time with customers and obviously with our investors. And so what stands out to me first and foremost is our colleagues are just awesome. Really an incredible team, mission driven, really understands the importance of every single component needs to be at the highest quality and obviously deliver for our customers.

So it's a really a towering strength, I would say. And we've been at it for a hundred years. And so
the technical depth in the team is another one that I think really is unmatched. With regards to areas for improvement or priorities, and I highlighted some of them in the prepared remarks, but but there is an opportunity to forge even closer relationships with our customers.

I would say currently
our points of connections are perhaps more at the operational, sort of technical level, and we're invited to elevate these relationships. And I think that's exciting because it will provide us with better insights, will really allow us to have opportunities to do demand planning together so that we ?have always the right capacity available as demands go up, and then improve the adoption of our innovation.

I think are some of the benefits of connecting with these customers at the more strategic level. And so that certainly will be an area of focus in the in the months to
?come. The second one is around continuous improvement. Obviously, that is part of what we do, but it's a muscle group that can be strengthened, I think. I think it's about being even more specific about the scale and dimensions of the impact we expect from continuous improvement, raise our ambitions, and then help our colleagues with some tools so that we can drive more benefits from digitization and automation and and just this general view of let's find a better way every day.

I I think that continues to be uh a real area across the sites but also in our global functions and
that will also be a priority to make sure that we define that well, help our colleagues uh through that and over time ?uh therefore deliver more impact from from that effort. Thanks for the question.

Passages & reports (12)
  • Yeah, no, thanks for the question. It's been a great first two months. Able to have spent …
  • colleagues are just awesome. Really an incredible team, mission driven, really understands…
  • the technical depth in the team is another one that I think really is unmatched. With rega…
  • our points of connections are perhaps more at the operational, sort of technical level, an…
  • have
  • always the right capacity available as demands go up, and then improve the adoption of our…
  • come.
  • The second one is around continuous improvement. Obviously, that is part of what we do, bu…
  • ambitions, and then help our colleagues with some tools so that we can drive more benefits…
  • that will also be a priority to make sure that we define that well, help our colleagues uh…
  • uh
  • therefore deliver more impact from from that effort. Thanks for the question.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. Our

Passages & reports (1)
  • you. Our

Speaker 0

next question comes from Larry Solo with CJS Securities. You may proceed.

Passages & reports (1)
  • next question comes from Larry Solo with CJS Securities. You may proceed.

Speaker 6

Great, thank you. And uh welcome, Michelle. Appreciate uh your opening remarks and and uh look forward to working with you and best of luck. Um I guess just first question, uh maybe just on the on the Bob on the margins. Um I know you you mentioned we're running a little bit ahead of that the hundred bips annual increase, but and you you kind of called out nothing really unusual in the quarter.

Um
?w was there, you know I know Q3 it was a strong revenue quarter, but is this kind of, you know, it was significantly ahead of our um our expectations. ?Um I realize smart dose was a little bit lower margin, but it's it's just kind of a new floor, like you know, should we look at kind of mid forties on the proprietary side as a as a a good starting point and growing from there or you know just kind ?of trying to um ?get a little bit better handle on

Passages & reports (10)
  • Great, thank you. And uh welcome, Michelle. Appreciate uh your opening remarks and and uh …
  • that the hundred bips annual increase, but and you you kind of called out nothing really u…
  • w
  • was there, you know I know Q3 it was a strong revenue quarter, but is this kind of, you kn…
  • Um
  • I realize smart dose was a little bit lower margin, but it's it's just kind of a new floor…
  • of
  • trying to um
  • get
  • a little bit better handle on

Speaker unclear

?that. Yeah,

Passages & reports (1)
  • that. Yeah,

Speaker 3

hey Larry, this is uh Bob. Uh appreciate the call. And uh yeah, you know I wouldn't I wouldn't say that uh this is the new floor, uh, but we are very uh optimistic about our continued margin expansion growth. Uh we didn't have any one timers in Q3, but it actually shows when you have the the mixed shift that we've seen, particularly in our HVP business, as well as that uh above expectation uh around growth, it shows really the the incremental margin strength that we have.

Um and and so we certainly uh in the quarter in in moving forward with the eliminate you know the with
the devestiture of smart dose that's going to be helpful for ?us. Um but uh you ?the three hundred basis points uh gross margin really was a combination of positive mixed shift, continued leveraging of our existing base given the strong performance that we've had from a from a filling the factories perspective.

Price was also a factor there um and then below the line being able to leverage our SGNA and
so forth. As we think about Q4, you know, we're still in line with very significant margin expansion year on year. We are probably investing a little in Q4 as we think about going forward. But I'd leave you with the expectation that I think that's one of the underappreciated opportunities for for us going forward.

And particularly
?with what Michelle was just talking about with continuous improvement, I think we're we we have an opportunity to continue to drive margin expansion going forward. So we're certainly um uh optimistic and and not done with uh uh driving that those margins over the next several years.

Passages & reports (11)
  • hey Larry, this is uh Bob. Uh appreciate the call. And uh yeah, you know I wouldn't I woul…
  • have the the mixed shift that we've seen, particularly in our HVP business, as well as tha…
  • the devestiture of smart dose that's going to be helpful for
  • us.
  • Um but uh you
  • the
  • three hundred basis points uh gross margin really was a combination of positive mixed shif…
  • so forth. As we think about Q4, you know, we're still in line with very significant margin…
  • opportunities for for us going forward. And particularly
  • with
  • what Michelle was just talking about with continuous improvement, I think we're we we have…

Speaker 0

Thank ?you. Our next question comes from Doug Schenkel with UBS. You may proceed.

Passages & reports (3)
  • Thank
  • you. Our
  • next question comes from Doug Schenkel with UBS. You may proceed.

Speaker 6

Good morning, and thank you for taking my questions. Um Michelle, I want to I want to start with one on uh your view of the portfolio today and and whether you see any gaps that represent opportunity as you think about technology, adjacent capabilities, you know, ?maybe new therapeutic categories.

Passages & reports (3)
  • Good morning, and thank you for taking my questions. Um Michelle, I want to I want to star…
  • maybe new
  • therapeutic categories.

Speaker unclear

?I I ask in

Passages & reports (1)
  • I I ask in

Speaker 3

part because ?you have a really successful history of MA most recently across your decade at Thermo. So I just just want to see how you're thinking about the portfolio and and really what is your MA criteria. And then if I could just ask my

Passages & reports (3)
  • part because
  • you have a
  • really successful history of MA most recently across your decade at Thermo. So I just just…

Speaker unclear

?my

Passages & reports (1)
  • my

Speaker 6

second one ?and then I'll

Passages & reports (3)
  • second one
  • and then
  • I'll

Speaker unclear

?I'll

Passages & reports (1)
  • I'll

Speaker 3

get back and listen.

Passages & reports (1)
  • get back and listen.

Speaker 6

Um

Passages & reports (1)
  • Um

Speaker 3

Year to date, you've ?grown glip

Passages & reports (3)
  • Year to date, you've
  • grown
  • glip

Speaker 6

revenue. Um, I think it's over thirty percent. That comes after a year of growing, you know, around fifty percent uh in the prior period. So robust growth against the tough comp. Um given this, is approximately 10% still the right planning assumption going forward for GLIP 1 revenue? Um it just seems like you're continued continuing to have just tremendous momentum there in spite of any concerns about you know generics, multi-dose or orals that you know were prevalent in investor discussions um earlier this year.

I'm just I'm just wondering if that 10% is still the right number. Thank

Passages & reports (2)
  • revenue. Um, I think it's over thirty percent. That comes after a year of growing, you kno…
  • revenue? Um it just seems like you're continued continuing to have just tremendous momentu…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Good questions. So on on portfolio and MA, this is how I uh sort of think about it. And obviously it's uh it's early. ?But the first thought is around uh the fact that our organic profile here at West is so incredibly strong. We have multiple secular growth tailwinds, an enviable market position, ?and a super capable team. That is what has earned this company its premium valuation.

And so the first focus will always be about continuing to strengthen the organic prospects of the company.
?Then having spent a lot of time with our customers here over the last ten plus years, it's also clear that they are looking for simplification of their supply chain and consolidation of

Passages & reports (7)
  • Good questions. So on on portfolio and MA, this is how I uh sort of think about it. And ob…
  • But
  • the first thought is around uh the fact that our organic profile here at West is so incred…
  • and
  • a super capable team. That is what has earned this company its premium valuation. And so t…
  • Then
  • having spent a lot of time with our customers here over the last ten plus years, it's also…

Speaker 3

their

Passages & reports (1)
  • their

Speaker 2

supplier base. It's hard for them to design supply chains when there's so many people involved that are responsive and resilient and economical. And so they're quite vocal on this point and have demonstrated that they would move market share towards their preferred partners. And we're on ?that very short list. And therefore have the opportunity to think about what else could we offer these customers and extend our impact.

Obviously, given our financial profile and and our organic prospects, the bar for MA is incredibly high. Um and that's a good thing uh from where I sit because it will allow us
to be incredibly patient, disciplined, uh to only pursue uh transactions that truly amplify our financial profile and be regarded as very favorable in the eyes of our customers, because then they will also deliver great uh value for our shareholders.

So um the organic focus I think
is what it will be, and and then over time, uh as I go through ?the uh the process here we'll we'll we'll think about ?uh what other opportunities may arise in the future. ?You know, on your point around uh GLP1 growth, um look the percentages indeed at some point um become harder to comp when you sort of uh roll roll them over, but I do think we stay incredibly bullish about the full prospects of that therapy class.

Um and again, as a company, we have
the great opportunity to participate in that market very broadly, right? Not only with the current players and continue to do a good job for them. Make sure that we're part of the new uh uh uh entries to the market and the new molecules that are being developed, and then of course ?the biosimilar players are the generic players.

So uh I feel good about the fact that um GOP one will continue to be an important uh driver of growth here in the in the periods to

Passages & reports (14)
  • supplier base. It's hard for them to design supply chains when there's so many people invo…
  • that
  • very short list. And therefore have the opportunity to think about what else could we offe…
  • to be incredibly patient, disciplined, uh to only pursue uh transactions that truly amplif…
  • is what it will be, and and then over time, uh as I go through
  • the
  • uh the process here we'll we'll we'll think about
  • uh
  • what other opportunities may arise in the future.
  • You know,
  • on your point around uh GLP1 growth, um look the percentages indeed at some point um becom…
  • the great opportunity to participate in that market very broadly, right? Not only with the…
  • the
  • biosimilar players are the generic players. So uh I feel good about the fact that um GOP o…

Speaker unclear

?come.

Passages & reports (1)
  • come.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. Our

Passages & reports (1)
  • you. Our

Speaker 0

next question comes from David Winley with Jeffries. He may proceed.

Passages & reports (1)
  • next question comes from David Winley with Jeffries. He may proceed.

Speaker unclear

?Hi. Good morning. Doug stole a lot of my thunder there.

Passages & reports (1)
  • Hi. Good morning. Doug stole a lot of my thunder there.

Speaker 7

Unverified voice label

Appreciate your answers on that. I wanted to ask, I guess, on um on capacity and the commentary around CapEx and thinking ?you know kind of strategically around ROI and Michelle, your and your comments about the strength of the organic franchise. Is is there an opportunity to drive efficiency into the footprint and s and supply the demand that you're seeing with a fairly what sounds like maybe a fairly efficient ?um capex expenditure for expansion or I guess I'm trying to feel out are we about to head into you know a multi year elevated capex spending regime again?

Passages & reports (6)
  • Appreciate your answers on that. I wanted to ask, I guess, on um on capacity and the comme…
  • you know
  • kind of strategically around ROI and Michelle, your and your comments about the strength o…
  • what sounds like maybe a fairly efficient
  • um
  • capex expenditure for expansion or I guess I'm trying to feel out are we about to head int…

Speaker 2

Thanks, Dave. Look at as as Bob mentioned, I think we're very comfortable with the six to eight percent sort of range. Um you know, some years you're at the lower end of that range, some years you're at the higher end of that range, ?but th this is not a place where I think we would be outside of it on either side. Um I I think your point around capacity is is a good one, right?

That that's why I also mentioned we have this opportunity around continuous improvement because a lot of that effort will be going towards debottlenecking
and increasing output from our current uh you know capacity. And so that has a a real focus and and we'll continue to strengthen that. And then in addition, as we mentioned, we are starting on the next wave of finishing capacity, and that's just new investment that will expand our available capacity so that we have the right capacity available for the continued growth of this business, but expect us to operate inside

Passages & reports (5)
  • Thanks, Dave. Look at as as Bob mentioned, I think we're very comfortable with the six to …
  • but th
  • this is not a place where I think we would be outside of it on either side. Um I I think y…
  • and increasing output from our current uh you know capacity. And so that has a a real focu…
  • expand our available capacity so that we have the right capacity available for the continu…

Speaker 3

that

Passages & reports (1)
  • that

Speaker 2

range as provided.

Passages & reports (1)
  • range as provided.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

and David, maybe just to add on what Michelle's saying, you know, one of the things that we've done internally in the last year is really be much more thoughtful about the priorities within the capital spend that we have. And so driving, I would say, disproportionate investment in our highest return areas, which would be HVP. So not only do we have the opportunity to continue to drive efficiencies within the factory footprint that we have through the continuous improvement that we're doing, we're also doing some tech transfers to better level load our facilities, which provides not only multiple sources of product to our customers, which is important, but it also helps us leverage the existing footprint even more efficiently.

And as we think about the upgrade opportunities to moving towards you know less and less
contamination, higher and higher regulatory requirements, that finishing capacity has a higher ROI. And it actually doesn't require, you know, the beauty of that is it doesn't require more units. It's really taking the existing units and upgrading them to higher value units. And so ?I feel like we've got a sufficient molding capacity, which is probably the higher areas of investment, and then continue to invest uh in advance of uh the uh HVP uh finishing activities that we've just talked

Passages & reports (6)
  • and David, maybe just to add on what Michelle's saying, you know, one of the things that w…
  • be HVP. So not only do we have the opportunity to continue to drive efficiencies within th…
  • not only multiple sources of product to our customers, which is important, but it also hel…
  • contamination, higher and higher regulatory requirements, that finishing capacity has a hi…
  • I
  • feel like we've got a sufficient molding capacity, which is probably the higher areas of i…

Speaker unclear

?about

Passages & reports (1)
  • about

Speaker unclear

?you our

Passages & reports (1)
  • you our

Speaker 0

next question comes from Luke Sergott with Barclays you may proceed

Passages & reports (1)
  • next question comes from Luke Sergott with Barclays you may proceed

Speaker unclear

?this is

Passages & reports (1)
  • this is

Speaker 4

Salemon for Luke thanks ?for taking our questions this morning um ?you know the the HHS fairly

Passages & reports (5)
  • Salemon for Luke thanks
  • for
  • taking our questions this morning um
  • you know
  • the the HHS fairly

Speaker 2

recently released a draft guidance that has some s similarities to to annex one sounds like you've already seen movement over to HVP components outside of

Passages & reports (1)
  • recently released a draft guidance that has some s similarities to to annex one sounds lik…

Speaker 4

Europe,

Passages & reports (1)
  • Europe,

Speaker 2

but just wanted to get

Passages & reports (1)
  • but just wanted to get

Speaker 4

an

Passages & reports (1)
  • an

Speaker 2

update on how you

Passages & reports (1)
  • update on how you

Speaker 4

see this affecting the market just from your

Passages & reports (1)
  • see this affecting the market just from your

Speaker unclear

?previous experience with how Annex One kind of progressed and how you expect things to trend

Passages & reports (1)
  • previous experience with how Annex One kind of progressed and how you expect things to tre…

Speaker 2

within the US.

Passages & reports (1)
  • within the US.

Speaker unclear

?And then also kind of

Passages & reports (1)
  • And then also kind of

Speaker 2

separately just wanted to hear an update on how drug handling ?is um progressing versus ?your expectations this quarter ?and and in for Q. Thanks. Well thanks for the questions. A good observation on the regulatory front. I I think

Passages & reports (7)
  • separately just wanted to hear an update on how drug handling
  • is
  • um progressing versus
  • your
  • expectations this quarter
  • and and in for
  • Q. Thanks. Well thanks for the questions. A good observation on the regulatory front. I I …

Speaker 3

this is sort of

Passages & reports (1)
  • this is sort of

Speaker 2

how

Passages & reports (1)
  • how

Speaker 3

these

Passages & reports (1)
  • these

Speaker 2

global regulators

Passages & reports (1)
  • global regulators

Speaker 3

work.

Passages & reports (1)
  • work.

Speaker 2

Sometimes one region is a little bit ahead with an insight and and a set of regulations and then others

Passages & reports (1)
  • Sometimes one region is a little bit ahead with an insight and and a set of regulations an…

Speaker 3

follow, right? And so the way I would think about it is the regulators in Europe when they publish their NX One requirements, obviously we're trying to solve a very specific problem around contamination, but that has nothing to do with being in Europe, right? It has everything to do with sort of how these products are being manufactured. And so it's quite logical for other regulators in the world to solve or focus on that same problem and suggest uh ways that companies need to comply.

And so we're seeing now very clearly that uh in the guidance uh that uh the US is now embarking on. And
I think our customers are used to that. So, you know, when they think about, for instance, upgrading to our H VP components, that's never a regional strategy. And so I I think it's uh it it's in our expectations that therefore um you know the broader regulatory push towards higher contamination will continue to be a real secular long term growth trend for ?us uh to uh to upgrade customers to uh even better even better solutions.

Yeah and and maybe to build on that, you know, most of the revenue upgrades that we've seen today have been the European based, but increasingly as we talk about those new
projects, those are in the pipeline. So that's more opportunity, I think, going forward. And as Michelle said, so seeing some nice pickup there, mainly on the on the project side. Um, but uh think that that's a multi-year kind of opportunity for us.

Passages & reports (7)
  • follow, right? And so the way I would think about it is the regulators in Europe when they…
  • products are being manufactured. And so it's quite logical for other regulators in the wor…
  • I think our customers are used to that. So, you know, when they think about, for instance,…
  • push towards higher contamination will continue to be a real secular long term growth tren…
  • us
  • uh to uh to upgrade customers to uh even better even better solutions. Yeah and and maybe …
  • projects, those are in the pipeline. So that's more opportunity, I think, going forward. A…

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 2

then on the point around drug

Passages & reports (1)
  • then on the point around drug

Speaker 3

handling uh and the sort of strategy in West Vantage, I I think it's progressing as per our expectations. Um so uh we continue to ramp up uh those uh higher value added uh uh contracts and continue to

Passages & reports (1)
  • handling uh and the sort of strategy in West Vantage, I I think it's progressing as per ou…

Speaker 2

see a good funnel of opportunities and team is doing a good job executing

Passages & reports (1)
  • see a good funnel of opportunities and team is doing a good job executing

Speaker 3

those and then ?of course are rolling off ?you know the more legacy uh um projects and and so I think that's why you see um you know sort of that muted effect on growth uh uh this year and and next

Passages & reports (5)
  • those and then
  • of
  • course are rolling off
  • you
  • know the more legacy uh um projects and and so I think that's why you see um you know sort…

Speaker 0

thank ?you. Our next question comes from Brendan Smith with T D Cowan. You may proceed.

Passages & reports (3)
  • thank
  • you. Our
  • next question comes from Brendan Smith with T D Cowan. You may proceed.

Speaker unclear

?Great,

Passages & reports (1)
  • Great,

Speaker 2

thanks for taking the questions guys. Uh and congrats again on the print, Michelle, it's great to have ?you. Um maybe one here on the revenue mix that we should think about moving ?forward. I I guess you guys noted that uh H VPs are over fifty percent now of revenues and some of which includes I think biologics around 43 percent you had in the DEX error. ?

So
I guess as we look at our models through Q4 and into next year, I guess where do you think that HVPIC the H excuse me HVP mix uh ultimately gets to over

Passages & reports (7)
  • thanks for taking the questions guys. Uh and congrats again on the print, Michelle, it's g…
  • you.
  • Um maybe one here on the revenue mix that we should think about moving
  • forward. I
  • I guess you guys noted that uh H VPs are over fifty percent now of revenues and some of wh…
  • So
  • I guess as we look at our models through Q4 and into next year, I guess where do you think…

Speaker 3

the next year? And and I guess just

Passages & reports (1)
  • the next year? And and I guess just

Speaker unclear

?related to that, how are you thinking

Passages & reports (1)
  • related to that, how are you thinking

Speaker 3

about

Passages & reports (1)
  • about

Speaker unclear

?you know where the current

Passages & reports (1)
  • you know where the current

Speaker 2

26 revenue exit run rate is tracking versus that seven to nine percent LRP you've put out there previously and just any updated thoughts on that looking ahead. Thanks.

Passages & reports (1)
  • 26 revenue exit run rate is tracking versus that seven to nine percent LRP you've put out …

Speaker unclear

?Yeah

Passages & reports (1)
  • Yeah

Speaker 2

maybe uh two thoughts. Uh one, I I I think the good thing about this business, as I mentioned earlier, is it benefits from multiple uh uh

Passages & reports (1)
  • maybe uh two thoughts. Uh one, I I I think the good thing about this business, as I mentio…

Speaker 3

tailwinds when it comes to growth. And so we think the upgrade opportunity is one that we will be with us, uh as we just talked about uh globally and and therefore um you know an important driver of revenue growth. And so you'll see the growth in that uh segment. But similarly on the biologic side, because that's driven by record scientific innovation, right?

And you we're sitting at a record pipeline in clinical development and a lot of that is biologics, increasing percentages. So also that segment will benefit from
these growth tailwinds. ?So I I

Passages & reports (5)
  • tailwinds when it comes to growth. And so we think the upgrade opportunity is one that we …
  • biologic side, because that's driven by record scientific innovation, right? And you we're…
  • these growth tailwinds.
  • So
  • I I

Speaker 2

think

Passages & reports (1)
  • think

Speaker 3

we feel

Passages & reports (1)
  • we feel

Speaker 2

good

Passages & reports (1)
  • good

Speaker 3

about

Passages & reports (1)
  • about

Speaker 2

all aspects of the portfolio qua you know benefiting from these from these trends and therefore we feel good about sort of the robustness of the growth profile of the overall company know going going forward.

Passages & reports (1)
  • all aspects of the portfolio qua you know benefiting from these from these trends and ther…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

and I I know you asked um Brendan about kind of revenue mix. We don't have a specific target um of uh revenue, ?but we do expect that HVP will be growing faster than the overall company. So you could expect that, you know, that number to continue to rise uh over time. Um and uh that's the the nice thing about uh this business is uh those secular tailwinds are in the areas that were providing most value to customers but also, you know, our our uh best performing products.

Passages & reports (4)
  • and I I know you asked um Brendan about kind of revenue mix. We don't have a specific targ…
  • but
  • we do expect that HVP will be growing faster than the overall company. So you could expect…
  • to customers but also, you know, our our uh best performing products.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you. Our

Passages & reports (1)
  • you. Our

Speaker 0

next question comes from Curtis Moyles with BNB Puribas. You may proceed.

Passages & reports (1)
  • next question comes from Curtis Moyles with BNB Puribas. You may proceed.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 6

good morning. Thanks for taking my question and welcome to the team Michelle looking forward to working with ?you. So I just wanted ?to start ?up on the biologics revenue. I know that's grown 60-26% year to date. So just kind of curious how sustainable that is going forward and ?maybe could ?we see ?that drop off since it's just ?a high level.

Passages & reports (15)
  • good morning. Thanks for taking my question and welcome to the team Michelle looking forwa…
  • you.
  • So I just wanted
  • to
  • start
  • up on the
  • biologics revenue. I know that's grown 60-26% year to date. So just kind of curious how su…
  • maybe
  • could
  • we
  • see
  • that drop off since
  • it's just
  • a
  • high level.

Speaker unclear

?And then

Passages & reports (1)
  • And then

Speaker 2

secondly, I just wanted to quickly ask on price as well. It was 4% of growth in the quarter. Should we expect that to kind of continue going forward? Thank

Passages & reports (1)
  • secondly, I just wanted to quickly ask on price as well. It was 4% of growth in the quarte…

Speaker unclear

?you. Yeah,

Passages & reports (1)
  • you. Yeah,

Speaker 2

so on biologics, um uh as I mentioned, we're we're very excited uh to see um the continued

Passages & reports (1)
  • so on biologics, um uh as I mentioned, we're we're very excited uh to see um the continued

Speaker 3

focus of of both

Passages & reports (1)
  • focus of of both

Speaker 2

pharma and biotech on developing you know impactful new medicines, right? And if you look at the the pace and the scale at which that innovation pipeline now sits, it's at all time records. Both true in terms of overall compounds that people are working on, but also true for the percentage of that that represents biologics, which is obviously super relevant to us because those uh will need to be delivered uh you know through injection.

And so I think you'll see real uh continued focus on uh that part

Passages & reports (2)
  • pharma and biotech on developing you know impactful new medicines, right? And if you look …
  • percentage of that that represents biologics, which is obviously super relevant to us beca…

Speaker 3

of it, because these large molecules are proven to be um you know really the key to addressing some of these unmet medical needs uh as as our customers are ?uh developing those products. So ?uh that you should see

Passages & reports (5)
  • of it, because these large molecules are proven to be um you know really the key to addres…
  • uh
  • developing those products. So
  • uh
  • that you should see

Speaker 2

as a continued uh driver of growth uh you know going forward. ?You know on price, uh I I I think uh we've always said two to three percent. I I think that is still sort of the right long term assumption. I I think this year uh a little ahead of it, you know, part of that has to do with the environment in which we find ourselves, but ?I I think the right planning assumption

Passages & reports (6)
  • as a continued uh driver of growth uh you know going forward.
  • You
  • know on price, uh I I I think uh we've always said two to three percent. I I think that is…
  • ourselves, but
  • I
  • I think the right planning assumption

Speaker 3

is probably the one that we talked about previously.

Passages & reports (1)
  • is probably the one that we talked about previously.

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?Our

Passages & reports (1)
  • Our

Speaker 0

next question comes from Macy Doc with Stevens. You may proceed.

Passages & reports (1)
  • next question comes from Macy Doc with Stevens. You may proceed.

Speaker 3

Hey, good morning, and thank you for taking my questions.

Passages & reports (1)
  • Hey, good morning, and thank you for taking my questions.

Speaker 2

Michelle, uh looking forward to working

Passages & reports (1)
  • Michelle, uh looking forward to working

Speaker 3

with you as well.

Passages & reports (1)
  • with you as well.

Speaker 2

Um maybe

Passages & reports (1)
  • Um maybe

Speaker 3

just a quick one to follow up on maybe Doug's question earlier, ?but you have a pretty unique multinational services background. Uh I just want ?to get a sense for how you're thinking about leveraging West Vantage in the future. It's an area that's, ?you know, maybe until recently was fairly underappreciated by investors. Uh so I just want to get a broader picture for how you're thinking about that platform long term.

Thanks.

Passages & reports (7)
  • just a quick one to follow up on maybe Doug's question earlier,
  • but you
  • have a pretty unique multinational services background. Uh I just want
  • to get
  • a sense for how you're thinking about leveraging West Vantage in the future. It's an area …
  • you know,
  • maybe until recently was fairly underappreciated by investors. Uh so I just want to get a …

Speaker 2

Yeah, thanks. Thanks, Mike, for the question. I think the if you look at our company, um, you know, the core of ?it uh are its products, right? That represents a vast, vast majority of the revenue, uh the profit, and I I think also sort of the financial profile as we've laid it out is really one of a of a products business. And so, you know, I I I think that's a an important observation. ?

I
think on West Vantage it's all about improving what we the business we have. And in my assessment, ?uh we have the right strategy, you know, moving towards the higher value added uh components, make sure we execute really well so that uh the contribution of that part part of the business uh continues to strengthen uh here and uh in the years ahead.

Passages & reports (7)
  • Yeah, thanks. Thanks, Mike, for the question. I think the if you look at our company, um, …
  • it
  • uh are its products, right? That represents a vast, vast majority of the revenue, uh the p…
  • I
  • think on West Vantage it's all about improving what we the business we have. And in my ass…
  • uh
  • we have the right strategy, you know, moving towards the higher value added uh components,…

Speaker 0

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Our next question comes from Aventica Dabario with Bank of America, you may proceed.

Passages & reports (1)
  • Our next question comes from Aventica Dabario with Bank of America, you may proceed.

Speaker 2

Hi, thank you for the question and congrats on the quarter. You're starting a new wave of um H V investments. Um when should that capacity come online and can your existing footprint support the demand you're seeing in the near term? Thank

Passages & reports (1)
  • Hi, thank you for the question and congrats on the quarter. You're starting a new wave of …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Thank you for your question. Um certainly not looking for more dots on the map. So you know I I think these investments are going into our existing uh uh footprint um and you know I I think the lead time of these projects uh is sort of similar to what we have experienced

Passages & reports (1)
  • Thank you for your question. Um certainly not looking for more dots on the map. So you kno…

Speaker 3

before, right? So uh if we start on these projects now,

Passages & reports (1)
  • before, right? So uh if we start on these projects now,

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 2

know the right assumption is probably 18, 24 months uh for those to come online and and deliver a meaningful contribution uh you know to the to the growth of uh of the company.

Passages & reports (1)
  • know the right assumption is probably 18, 24 months uh for those to come online and and de…

Speaker 3

Yeah and and just the to follow on to that, I think you know with the existing capacity that we have, we feel good about continuing to support um the demand. We've made uh a significant investments in um labor uh to increase capacity at uh primarily several of our HPP sites. We've been able to see that pr you know drive the the performance and and and would expect us to be able to to continue to you know increase capacity uh uh within that footprint as this comes online.

Passages & reports (2)
  • Yeah and and just the to follow on to that, I think you know with the existing capacity th…
  • We've been able to see that pr you know drive the the performance and and and would expect…

Speaker 0

Thank you. And I see no further questions. This concludes the conference. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • Thank you. And I see no further questions. This concludes the conference. Thank you for yo…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

1 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 1. Unassigned words: 220. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T21:47:04.265Z.
Transcript version v1-93b2750ab9fab451a815 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.